
First-Line Options for Non–Clear Cell RCC
Moshe C. Ornstein, MD, MA, of Cleveland Clinic tells Elizabeth R. Plimack, MD, MS, of Fox Chase Cancer Center that non–clear cell renal cell carcinoma (RCC) now has prospective first-line data, where guidelines a few years ago offered only a clinical trial or cabozantinib alone.
Episodes in this series

Moshe C. Ornstein, MD, MA, of Cleveland Clinic tells Elizabeth R. Plimack, MD, MS, of Fox Chase Cancer Center that non–clear cell renal cell carcinoma (RCC) now has prospective first-line data, where guidelines a few years ago offered only a clinical trial or cabozantinib alone. He cites a small single-arm phase 2 study of cabozantinib plus nivolumab in about 40 patients, with roughly a 50% response rate, progression-free survival near 12 months, and little activity in chromophobe disease. He leans more on lenvatinib plus pembrolizumab based on KEYNOTE-B61, a larger single-arm study of about 160 patients across subtypes, quoting a response rate of about 50%, progression-free survival of about 18 months, and overall survival now over 40 months. He orders somatic and genetic testing, stresses that papillary, chromophobe, translocation, and unclassified tumors differ, and recommends specialist referral for options such as erlotinib plus bevacizumab in papillary disease or mammalian target of rapamycin (mTOR) inhibitors in chromophobe disease.
Related to this article








